Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (291-300 of 332) with videos related to

Pageof 34
Sort By:
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Urology|September 12, 2018
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline RecommendationsAxel Bex, Laurence Albiges, Michael Staehler, et al.
BJU International|May 8, 2021
Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancerTeele Kuusk, David Cullen, Joana Briosa Neves, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Urologic Oncology|September 20, 2022
Recurrence pattern in localized RCC: results from a European multicenter database (RECUR)Giuseppe Fallara, Alessandro Larcher, Saeed Dabestani, et al.
BJU International|May 28, 2021
Growth and renal function dynamics of renal oncocytomas in patients on active surveillanceJoana B Neves, Rebecca Varley, Stefano Agnesi, et al.
European Urology Open Science|June 17, 2026
Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]Leo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
International Journal of Surgery (London, England)|October 30, 2020
A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold siteVeeru Kasivisvanathan, Jamie Lindsay, Sara Rakshani-Moghadam, et al.
European Urology Open Science|January 15, 2026
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy TrialsLeo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
Pageof 34

Showing results (291-300 of 332) with videos related to

Sort By:
Pageof 34
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Urology|September 12, 2018
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline RecommendationsAxel Bex, Laurence Albiges, Michael Staehler, et al.
BJU International|May 8, 2021
Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancerTeele Kuusk, David Cullen, Joana Briosa Neves, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Urologic Oncology|September 20, 2022
Recurrence pattern in localized RCC: results from a European multicenter database (RECUR)Giuseppe Fallara, Alessandro Larcher, Saeed Dabestani, et al.
BJU International|May 28, 2021
Growth and renal function dynamics of renal oncocytomas in patients on active surveillanceJoana B Neves, Rebecca Varley, Stefano Agnesi, et al.
European Urology Open Science|June 17, 2026
Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]Leo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
International Journal of Surgery (London, England)|October 30, 2020
A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold siteVeeru Kasivisvanathan, Jamie Lindsay, Sara Rakshani-Moghadam, et al.
European Urology Open Science|January 15, 2026
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy TrialsLeo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
Pageof 34